17.2 Class I: Sodium Channel Blockers

Sodium channel blockers regulate heart rhythm by slowing electrical conduction through cardiac tissue and prolonging refractory periods. As Class I antidysrhythmics, they're subdivided into three groups (IA, IB, IC) based on how strongly they block sodium channels and how they affect action potential duration. Understanding these differences matters because each subclass treats different arrhythmias and carries distinct risks.

For nursing practice, the key priorities are monitoring ECG changes, recognizing toxicity early, and educating patients about the importance of adherence and reporting new symptoms.

Class I: Sodium Channel Blockers

Characteristics of Class I Sodium Channel Blockers

During Phase 0 of the cardiac action potential, sodium rushes into cardiac cells to trigger rapid depolarization. Class I drugs block these sodium channels, which does two things: it slows conduction velocity (how fast the electrical signal travels) and prolongs the refractory period (the window when cardiac cells can't be re-excited). Together, these effects suppress the two most common mechanisms behind dysrhythmias: ectopic foci (abnormal pacemaker sites firing on their own) and reentrant circuits (electrical signals looping back on themselves).

The three subclasses differ in how aggressively they block sodium channels and what they do to action potential duration (APD):

• Class IA: Moderate sodium channel blockade and prolongs APD. Examples: quinidine, procainamide, disopyramide.
• Class IB: Mild sodium channel blockade and shortens APD. Examples: lidocaine, mexiletine.
• Class IC: Strong sodium channel blockade with minimal effect on APD. Examples: flecainide, propafenone.

This distinction is clinically important. For instance, Class IA drugs carry more risk of QT prolongation because they lengthen APD, while Class IC drugs are the most potent at slowing conduction but are reserved for patients without structural heart disease due to proarrhythmic risk.

Cardiac Electrophysiology and Class I Antidysrhythmics

The cardiac action potential has two main electrical events: depolarization (sodium influx, creating the electrical impulse) and repolarization (potassium efflux, resetting the cell). Class I drugs target the depolarization phase specifically by blocking sodium channels.

By slowing sodium entry, these drugs reduce how quickly cardiac cells can fire and spread electrical signals. This modification of the refractory period means the heart needs more time before it can generate another action potential. The practical result: abnormal rhythms from ectopic foci get suppressed because those cells can't fire as easily, and reentrant circuits get interrupted because the signal can't complete its loop before the tissue becomes refractory.

Indications and Reactions of Antidysrhythmic Drugs

Indications

• Ventricular tachycardia and ventricular fibrillation: Abnormally fast, potentially life-threatening rhythms originating in the ventricles. Class IA and IB drugs are commonly used here.
• Supraventricular tachycardias: Fast rhythms originating above the ventricles, including atrial fibrillation and atrial flutter. Class IA and IC drugs are typical choices.
• Premature ventricular contractions (PVCs): Early heartbeats from the ventricles. Treatment depends on frequency and whether the patient is symptomatic.

Adverse Reactions

• Proarrhythmic effects: Paradoxically, these drugs can worsen or create new dysrhythmias. This is the most dangerous adverse effect and the reason close monitoring is essential.
• Hypotension and negative inotropic effects: Sodium channel blockade reduces cardiac contractility (the heart's pumping strength), which can drop blood pressure.
• Neurological symptoms: Dizziness, confusion, and tremors, particularly with lidocaine toxicity.
• GI disturbances: Nausea, vomiting, and diarrhea are common, especially with quinidine.

Drug Interactions

• QT-prolonging medications (certain antibiotics like azithromycin, antipsychotics like haloperidol): Additive QT prolongation increases the risk of torsades de pointes, a dangerous form of ventricular tachycardia.
• Hepatic metabolism inhibitors (cimetidine, certain azole antifungals): These reduce drug clearance, raising serum levels and toxicity risk.
• Other cardiodepressants (beta-blockers, calcium channel blockers): Combining these with Class I drugs can dangerously enhance negative inotropic effects, leading to severe hypotension or heart failure.

Nursing Considerations for Sodium Channel Blockers

Before starting therapy, establish a baseline: obtain a 12-lead ECG, vital signs, and a focused cardiac assessment. Then monitor consistently throughout treatment.

Watch for these signs of toxicity or proarrhythmic effects:

1. ECG changes: QRS widening greater than 50% from baseline, QT prolongation, or new dysrhythmias
2. Hemodynamic instability: Hypotension, bradycardia, or signs of decreased cardiac output
3. Neurological symptoms: Dizziness, confusion, visual changes, or tremors

Additional nursing priorities:

• Check renal and hepatic function before and during therapy. Many Class I drugs are hepatically metabolized and renally excreted, so impaired organ function requires dose adjustments.
• Administer medications at the prescribed dose, route, and timing. Some Class I drugs (like lidocaine) are given IV only, while others (like flecainide) are oral.
• Keep emergency equipment at the bedside: defibrillator, resuscitation medications (epinephrine, atropine), and airway management supplies.
• Communicate ECG changes or new symptoms to the provider promptly. Collaborate with the healthcare team to adjust therapy as needed.

Patient Education for Class I Antidysrhythmics

• Take medications exactly as prescribed. Abruptly stopping can cause rebound dysrhythmias, so patients should never discontinue without consulting their provider.
• Report these symptoms immediately: new or worsening palpitations, dizziness, lightheadedness, fainting, or unusual fatigue. These could signal proarrhythmic effects or toxicity.
• Inform all healthcare providers (including dentists and surgeons) about antidysrhythmic use before any procedures, since drug interactions with anesthetics are a real concern.
• Check with the prescriber before taking any new medications, including over-the-counter products and herbal supplements. Even common products like antacids (cimetidine) can alter drug levels.
• Support heart health with lifestyle habits:
  • Regular physical activity as tolerated
  • A balanced, heart-healthy diet
  • Stress management techniques
  • Avoiding tobacco and limiting alcohol intake
• Keep written medication information accessible at home, and bring a current medication list to every appointment.